Safety and Immunogenicity of COVID-19 Vaccine, Inactivated in Healthy Population Aged From 3 to 11 Years

An Open-labelled, Bridging Phase Ⅲ Clinical Trial to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine in Healthy Population Aged From 3 to 11 Years

This is an open-labelled, bridging phase Ⅲ clinical trial of COVID-19 Vaccine manufactured by Sinovac Research & Development Co., Ltd. The main purpose of this study is to evaluate the superiority of the COVID-19 Vaccine in healthy population aged from 3 to 11 years against that in adults aged 18-26 years.

Study Overview

• Status: Completed
• Conditions: COVID-19
• Intervention / Treatment: Biological: COVID-19 Vaccine,Inactivated

Detailed Description

This study is a single-center, open-labelled, bridging phase Ⅲ clinical trial of COVID-19 Vaccine.The main purpose of this study is to evaluate the superiority of the COVID-19 Vaccine in healthy population aged from 3 to 11 years against that in adults aged 18-26 years.This study (PRO-nCOV-3002-1) will be used as a sub-trial of the Phase Ⅲ global multi-center clinical trial in children and adolescents(PRO-nCOV-3002) to provide safety and immunogenicity data.A total of 1000 healthy children aged 3-11 years will be enrolled ,including 500 children aged 3-5 years and 500 children aged 6-11 years.All subjects will receive 2 doses of experimental vaccine (600SU) with an interval of 28 days,and adverse reactions/events will be collected from all subjects after each dose and SAE and AESI monitoring will be completed from the beginning of vaccination to 6 and 12 months after full vaccination to evaluate the safety of the vaccine.About 3.0-3.5ml of venous blood will be collected from all subjects before immunization, 28 days after the whole immunization, 6 months after the whole immunization and 12 months after the whole immunization. Neutralizing antibody and S antibody will be detected to evaluate the immunogenicity and immune persistence of the vaccine.

• Study Type: Interventional
• Enrollment (Actual): 1000
• Phase: Phase 3

Contacts and Locations

Study Locations

• China
  • Jiangsu
    • Yancheng, Jiangsu, China, 224300
      • Sheyang County Center for Disease Control and Prevention

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 3 years to 11 years (Child)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Healthy participants aged 3-11 years;
• The participants and/or their guardians are able to understand and sign the informed consent voluntarily (in accordance with the local regulations)(For subjects aged 3-7years ,guardians need to sign the informed consent form,for subjects aged 8-17 years, both subjects and guardians need to sign the informed consent form);
• Able to comply with study procedures based on the assessment of the Investigator
• Must be willing to provide verifiable identification (in accordance with the local regulations), has means to be contacted and to contact the investigator during the study.

Exclusion Criteria:

• History of SARS-CoV-2 infection;
• Close contact with a confirmed COVID-19 within 14 days prior to randomization;
• Prior administration of an investigational coronavirus vaccine or current/ planned simultaneous participation in another interventional study to prevent or treat COVID-19;
• Allergy to vaccines or vaccine/placebo ingredients, and serious adverse reactions to vaccines, such as urticaria, dyspnea, angioneuroedema;
• Personal or first-grade relative (siblings) history of multisystem inflammatory disease in children (MIS-C);
• Significant chronic illnesses that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion (may include, but are not limited to cardiovascular disease, liver or kidney disorders, respiratory illnesses);
• Significant chronic central nervous system diseases or neuromuscular disorders, psychosis or severe cognitive behavioral disorder, in the opinion of the investigator, including epilepsy, autism spectrum disorder, intellectual disabilities (excluding Down Syndrome);
• Acute central nervous system diseases such as encephalitis/myelitis, acute disseminating encephalomyelitis, and related disorders;
• History of autoimmune and/or haematological diseases (including but not limited to systemic lupus erythematosus, thyroidectomy, autoimmune thyroid disease, any form of malignant tumor, asplenia, functional asplenia, or splenectomy resulting from any condition); well controlled type I diabetes mellitus is allowed;
• History of bleeding disorders (e.g. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venipuncture;

• Immunosuppressive therapy (systemic corticoid therapy, e.g. prednisone

  ≥2 mg/Kg/d or ≥20 mg/day for >14 days), cytotoxic therapy (antineoplastic chemotherapy, radiation therapy), (excluding topical or aerosol corticosteroid therapy) in the past 6 months;

• Receipt of blood products or immunoglobulins in the past 3 months;
• Receipt of other investigational drugs in the past 30 days;
• Receipt of attenuated live vaccines in the past 14 days;
• Receipt of inactivated or subunit vaccines in the past 7 days;
• Acute exacerbation or presentation of stable chronic diseases (including but not limited to asthma, migraine, gastrointestinal disorder, etc;
• Acute febrile illness with oral temperature >37.7°C ,enrollment could be considered if the fever is absent for 72 hours;
• Any confirmed or suspected human immunodeficiency virus (HIV) infection;
• Children in care or under a court order;
• According to the investigator's judgment, the subject has any other factors that might interfere with the results of the clinical trial or pose additional risk to the subject due to participation in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 3-5 years old age group; 500 participants aged 3-5 years will receive two doses of COVID-19 vaccine,inactivated on day 0 and day 28.	Biological: COVID-19 Vaccine,Inactivated; The COVID-19 vaccine,inactivated was manufactured by Sinovac Research& Development Co., Ltd..600SU Inactivated SARS-COV-2 virus in 0·5 mL of aluminium hydroxide solution per injection; Other Names: CoronaVac
Experimental: 6-11 years old age group; 500 participants aged 6-11 years will receive two doses of COVID-19 vaccine,inactivated on day 0 and day 28.	Biological: COVID-19 Vaccine,Inactivated; The COVID-19 vaccine,inactivated was manufactured by Sinovac Research& Development Co., Ltd..600SU Inactivated SARS-COV-2 virus in 0·5 mL of aluminium hydroxide solution per injection; Other Names: CoronaVac

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Immunogenicity index-the GMT of neutralizing antibodies	The GMT of neutralizing antibodies 28 days after the second vaccination.	28 days after the second vaccination

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Immunogenicity index-the seroconversion rate of neutralizing antibodies	The seroconversion rate of neutralizing antibodies 28 days after the second vaccination	28 days after the second vaccination
Immunogenicity index-the seropositive rate of neutralizing antibodies 28 days after the second vaccination	The seropositive rate of neutralizing antibodies 28 days after the second vaccination	28 days after the second vaccination
Immunogenicity index-GMI of neutralizing antibodies	GMI of neutralizing antibodies 28 days after the second vaccination	28 days after the second vaccination
Immunogenicity index-The seroconversion rate of the S antibody to SARS-CoV-2	The seroconversion rate of the S antibody to SARS-CoV-2 28 days after the second vaccination	28 days after the second vaccination
Immunogenicity index-The seropositivity rate of the S antibody to SARS-CoV-2	The seropositivity rate of the S antibody to SARS-CoV-2 28 days after the second vaccination	28 days after the second vaccination
Immunogenicity index-GMC of the S antibody to SARS-CoV-2	GMC of the S antibody to SARS-CoV-2 28 days after the second vaccination	28 days after the second vaccination
Immunogenicity index-GMI of the S antibody to SARS-CoV-2	GMI of the S antibody to SARS-CoV-2 28 days after the second vaccination	28 days after the second vaccination
Immunogenicity index-The seropositive rate of neutralizing antibodies	The seropositive rate of neutralizing antibodies 6 months/12 months days after the second vaccination	6 months/12 months days after the second vaccination
Immunogenicity index-GMT of neutralizing antibodies	GMT of neutralizing antibodies 6 months/12 months days after the second vaccination	6 months/12 months days after the second vaccination
Immunogenicity index-The seropositivity rate of the S antibody to SARS-CoV-2	The seropositivity rate of the S antibody to SARS-CoV-2 6 months/12 months days after the second vaccination	6 months/12 months days after the second vaccination
Immunogenicity index-GMC of the S antibody to SARS-CoV-2	GMC of the S antibody to SARS-CoV-2 6 months/12 months days after the second vaccination	6 months/12 months days after the second vaccination
Safety index-Incidence rate of adverse reactions	Incidence rate of adverse reactions occured from the beginning of the vaccination to 28 days after the second dose vaccination	From the beginning of the vaccination to 28 days after the second dose vaccination
Safety index-Incidence rate of SAEs	Incidence rate of SAEs from the beginning of the vaccination to 6 months after the second dose vaccination.	From the beginning of the vaccination to 6 months after the second dose vaccination
Safety index-Incidence rate of AESIs	Incidence rate of AESIs from the beginning of the vaccination to 6 months after the second dose vaccination	From the beginning of the vaccination to 6 months after the second dose vaccination

Collaborators and Investigators

• Sponsor: Sinovac Research and Development Co., Ltd.
• Investigators: Principal Investigator: Hongxing Pan, Master, Jiangsu Provincial Center for Disease Prevention and Control

Study record dates

Study Major Dates

• Study Start (Actual): November 27, 2021
• Primary Completion (Actual): January 27, 2023
• Study Completion (Actual): January 27, 2023

Study Registration Dates

• First Submitted: November 26, 2021
• First Submitted That Met QC Criteria: November 26, 2021
• First Posted (Actual): November 30, 2021

Study Record Updates

• Last Update Posted (Actual): October 16, 2023
• Last Update Submitted That Met QC Criteria: October 12, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19
• Other Study ID Numbers: PRO-nCOV-3002-1

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No